Can an antidepressant stop migraines before they start?

NCT ID NCT07385755

Ongoing Prevention Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether desvenlafaxine, a drug typically used for depression, can help prevent migraines in adults who have frequent attacks. Researchers will compare the drug to a placebo in 440 participants over 12 weeks. The goal is to see if it reduces the number of migraine days per month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Desvenlafaxine
What this could lead to: If it works, this could provide a new option for preventing frequent migraines, reducing the number of headache days per month.
What could go wrong: This is a mid-stage trial with no phase designation, so results are not yet confirmed. Desvenlafaxine may cause side effects like nausea or dizziness, and it might not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.